Zanidatamab: A New Frontier in Treating HER2-Positive Biliary Tract Cancer With James Harding, MD
The FDA's recent accelerated approval of zanidata…
Oncology Data Advisor · i3 Health
December 10, 202417m 26s
Audio is streamed directly from the publisher (podtrac.com) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
The FDA's recent accelerated approval of zanidatamab marks a significant breakthrough in the treatment landscape for human epidermal growth factor receptor 2 (HER2)–positive biliary tract cancer (BTC). Following the approval, Dr. James Harding, Associate Attending Physician in the Gastrointestinal Oncology and Early Drug Development Services at Memorial Sloan Kettering Cancer Center, sat down to provide oncology clinicians with insights into its significance and implications for clinical practice.
Learn more at: https://oncdata.com/zanidatamab-biliary-tract-cancer-james-harding/